- Home
- LSBPW vs MA Comparison
LSBPW vs MA Comparison
Compare LSBPW & MA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBPW
- MA
- Stock Information
- Founded
- LSBPW N/A
- MA 1966
- Country
- LSBPW China
- MA United States
- Employees
- LSBPW 758
- MA N/A
- Industry
- LSBPW Biotechnology: Pharmaceutical Preparations
- MA Business Services
- Sector
- LSBPW Health Care
- MA Consumer Discretionary
- Exchange
- LSBPW Nasdaq
- MA Nasdaq
- Market Cap
- LSBPW N/A
- MA N/A
- IPO Year
- LSBPW N/A
- MA 2006
- Fundamental
- Price
- LSBPW $0.05
- MA $528.03
- Analyst Decision
- LSBPW
- MA Strong Buy
- Analyst Count
- LSBPW 0
- MA 24
- Target Price
- LSBPW N/A
- MA $567.17
- AVG Volume (30 Days)
- LSBPW N/A
- MA 2.8M
- Earning Date
- LSBPW N/A
- MA 01-29-2025
- Dividend Yield
- LSBPW N/A
- MA 0.50%
- EPS Growth
- LSBPW N/A
- MA 15.35
- EPS
- LSBPW N/A
- MA 13.23
- Revenue
- LSBPW N/A
- MA $27,226,000,000.00
- Revenue This Year
- LSBPW N/A
- MA $15.28
- Revenue Next Year
- LSBPW N/A
- MA $12.21
- P/E Ratio
- LSBPW N/A
- MA $39.92
- Revenue Growth
- LSBPW N/A
- MA 11.73
- 52 Week Low
- LSBPW N/A
- MA $416.53
- 52 Week High
- LSBPW N/A
- MA $537.13
- Technical
- Relative Strength Index (RSI)
- LSBPW N/A
- MA 53.37
- Support Level
- LSBPW N/A
- MA $519.71
- Resistance Level
- LSBPW N/A
- MA $537.13
- Average True Range (ATR)
- LSBPW 0.00
- MA 8.51
- MACD
- LSBPW 0.00
- MA -1.06
- Stochastic Oscillator
- LSBPW 0.00
- MA 52.00
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.